BioSpace News Archive

Completion of balstilimab BLA filing on target for 1H 2021 New clinical data for AGEN1181 to be presented at AACR TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 iNKT cell therapy cancer trials to commence in 1H 2021

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that it will report financial results for the fourth quarter and full year 2020 and provide a corporate update on Wednesday, March 17, 2021, before the U.S. financial markets open

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs

Histogen Inc. (NASDAQ: HSTO), today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that the Company satisfactorily addressed all clinical hold questions and can proceed with initiation of the planned Phase 1/2 clinical trial of HST-003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003)

STRATA Skin Sciences, Inc. (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the publication of an independent study on the treatment of vitiligo using the Company’s XTRAC excimer laser

Oryzon will consequently proceed to file an IND application PORTICO will be developed in several US and European sites MADRID, Spain and CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces a constructive and successful pre-IND meeting with the FDA for the clinical development of vafidemstat

BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing

2020 Revenues Increase Over 330% Year-over-Year to Record $3.2 Million Murata Confirms XBAR® Performance and Moves Into Manufacturing Development Phase of Agreement

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that studies conducted with its BMB proprietary 5-HT2C agonists show robust efficacy in rodent models of opioid self-administration as a treatment for opioid use disorder (“OUD”).